Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
26.03
+3.46 (15.33%)
At close: Feb 4, 2025, 4:00 PM
25.03
-1.00 (-3.84%)
After-hours: Feb 4, 2025, 7:28 PM EST
Aligos Therapeutics Revenue
Aligos Therapeutics had revenue of $1.27M in the quarter ending September 30, 2024, a decrease of -60.82%. This brings the company's revenue in the last twelve months to $6.00M, down -63.40% year-over-year. In the year 2023, Aligos Therapeutics had annual revenue of $15.53M with 11.66% growth.
Revenue (ttm)
$6.00M
Revenue Growth
-63.40%
P/S Ratio
25.91
Revenue / Employee
$90,864
Employees
66
Market Cap
96.61M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
ALGS News
- 7 weeks ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - GlobeNewsWire
- 3 months ago - Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Aligos Therapeutics Appoints David Perry as Vice President of Business Development - GlobeNewsWire
- 4 months ago - Aligos Therapeutics to Present at Investor Conferences in October - GlobeNewsWire
- 4 months ago - Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - GlobeNewsWire
- 4 months ago - Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 - GlobeNewsWire
- 6 months ago - Aligos Therapeutics Announces Reverse Stock Split - GlobeNewsWire